ResMed Inc (RMD)vsDentsply Sirona Inc (XRAY)
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
XRAY
Dentsply Sirona Inc
$11.68
+1.88%
HEALTHCARE · Cap: $2.33B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 47% more annual revenue ($5.40B vs $3.68B). RMD leads profitability with a 27.5% profit margin vs -16.3%. XRAY appears more attractively valued with a PEG of 0.77. RMD earns a higher WallStSmart Score of 70/100 (B).
RMD
Strong Buy70
out of 100
Grade: B
XRAY
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Intrinsic value data unavailable for XRAY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
No major concerns identified
Operating margin of 1.8%
ROE of -36.4% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : XRAY
The strongest argument for XRAY centers on PEG Ratio, Price/Book. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Bear Case : XRAY
The primary concerns for XRAY are Operating Margin, Return on Equity, Profit Margin.
Key Dynamics to Monitor
RMD profiles as a mature stock while XRAY is a turnaround play — different risk/reward profiles.
XRAY carries more volatility with a beta of 0.93 — expect wider price swings.
RMD is growing revenue faster at 11.0% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 56/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Dentsply Sirona Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?